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Background and purpose Phosphodiesterases PDE3 and/or PDE4 control ventricular effects 
of catecholamines in several species but their relative effects in failing human ventricle are 
unknown. We investigated whether the PDE3-selective inhibitor cilostamide (0.3-1μM) or 
PDE4 inhibitor rolipram (1-10μM) modified the positive inotropic and lusitropic effects of 
catecholamines in human failing myocardium.  
Experimental approach Right and left ventricular trabeculae from freshly explanted hearts 
of 5 non-β-blocker-treated and 15 metoprolol-treated patients with terminal heart failure were 
paced to contract at 1Hz. The effects of (-)-noradrenaline, mediated through β1-adrenoceptors 
(β2-adrenoceptors blocked with ICI118551), and (-)-adrenaline, mediated through β2-
adrenoceptors (β1-adrenoceptors blocked with CGP20712A), were assessed in the absence 
and presence of PDE inhibitors. Catecholamine potencies were estimated from –logEC50s. 
Key results Cilostamide did not significantly potentiate the inotropic effects of the 
catecholamines in non-β-blocker-treated patients. Cilostamide caused greater potentiation 
(P=0.037) of the positive inotropic effects of (-)-adrenaline (0.78±0.12 log units) than (-)-
noradrenaline (0.47±0.12 log units) in metoprolol-treated patients. Lusitropic effects of the 
catecholamines were also potentiated by cilostamide. Rolipram did not affect the inotropic 
and lusitropic potencies of (-)-noradrenaline or (-)-adrenaline on right and left ventricular 
trabeculae from metoprolol-treated patients.  
Conclusions and implications Metoprolol induces a control by PDE3 of ventricular effects 
mediated through both β1- and β2-adrenoceptors, thereby further reducing sympathetic 
cardiostimulation in patients with terminal heart failure. Concurrent therapy with a PDE3 
blocker and metoprolol could conceivably facilitate cardiostimulation evoked by adrenaline 
through β2-adrenoceptors. PDE4 does not appear to reduce inotropic and lusitropic effects of 
catecholamines in failing human ventricle.   
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Introduction 
Activation of β1- and β2-adrenoceptors (β1ARs, β2ARs) of human failing ventricle by 
noradrenaline and adrenaline causes similar inotropic, lusitropic and biochemical effects 
through the cAMP/cAMP-dependent protein kinase (PKA) pathway (Kaumann et al., 1999). 
Phosphodiesterases (PDEs) break down cAMP. At least 21 genes of 11 PDE families are 
known (Bender and Beavo, 2006). The cAMP-hydrolysing isoenzymes PDE1, PDE2, PDE3, 
PDE4 and PDE8 are expressed in mammalian heart and PDE3 is particularly highly 
expressed in human myocardium (Osadchii, 2007). PDE3 is relevant to heart failure in which 
cardiac cAMP levels and function are depressed (Von der Leyen et al., 1991). By preventing 
cAMP hydrolysis, PDE3 inhibitors (e.g. milrinone and enoximone) enhance cardiac 
contractility through activation of cAMP-dependent pathways. Short-lasting infusions or low-
dose oral treatment with PDE3 inhibitors have been shown to improve systolic function in 
chronic heart failure (Van Tassel et al., 2008). In contrast, high-dose chronic treatment with 
PDE3 inhibitors worsens heart failure and increases mortality, particularly through sudden 
death (Amsallem et al., 2005). We hypothesize that the PDE3 activity in severe heart failure 
further reduces harmful cardiostimulation by endogenous catecholamines in β blocker-treated 
patients. It is unknown whether blockade of β1ARs and/or β2ARs in heart failure (Bristow, 
2000) can modify PDE3 activity.   
 
PDE4 is also expressed in human myocardium (Osadchii, 2007) and in particular PDE4D 
(Johnson et al., 2012), but its functions are not yet clear. PDE4D3 is an integral component of 
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the murine and human cardiac ryanodine RyR2 receptor complex and it is reduced in murine 
and human heart failure (Lehnhart et al., 2005). Therefore, PDE4D3 plausibly may affect 
catecholamine-evoked contractility. PDE4 controls the inotropic effects and cAMP signals of 
catecholamines, mediated through β1AR in rodent myocardium (Nikolaev et al., 2006; 
Rochais et al., 2006; Galindo-Tovar and Kaumann, 2008; Christ et al., 2009) but not in 
human atrium (Christ et al., 2006a; Kaumann et al., 2007). However, it is unknown whether 
PDE4 controls human ventricular effects of catecholamines and whether it is through β1AR 
and/or β2AR.  
 
We now investigated whether the inotropic and lusitropic effects of the catecholamines, 
mediated through β1AR or β2AR of ventricular trabeculae from patients with terminal heart 
failure, are enhanced by PDE3 inhibition with cilostamide and/or PDE4 inhibition with 
rolipram. We compared results from patients not treated with β-blocker or chronically treated 
with metoprolol. The results suggest that chronic treatment with metoprolol facilitates PDE3 
activity to reduce the inotropic and lusitropic effects of (-)-noradrenaline and (-)-adrenaline, 
mediated through β1ARs and β2ARs. PDE4 does not modify the effects of catecholamines.  
 
A progress report of this work was presented to a Biochemical Society Meeting (Christ et al., 
2006b). 
 5
Methods  
 
Heart Transplant Patients 
Written informed consent was obtained from all patients. Patients with terminal heart failure 
underwent heart transplant surgery at The Prince Charles Hospital, Brisbane, ethics approval 
numbers EC9876, HREC10/QPCH/184 and Gustav Carus Hospital, Dresden Technological 
University ethics committee (Document EK 1140 82202). Clinical data from Brisbane and 
Dresden patients are shown in Supplement Table S1A,B. Clinical data from Oslo patients are 
shown in Supplement Table S1C. All subjects or next of kin gave written informed consent to 
participate in the study, which was approved by the ethics committee in South-Eastern 
Norway Regional Health Authority (#S05172).  
 
  
Isolated ventricular trabeculae from heart transplant patients 
 
Right or left ventricular trabeculae were dissected, mounted on to tissue electrode blocks and 
electrically paced at 1 Hz to contract as described (Kaumann et al., 1999). For further details 
see Supplement.  
 
Specific activation of β1- and β2-adrenoceptors  
To determine the effects of β1AR (Alexander et al., 2011) -selective activation, 
concentration-effect curves for (-)-noradrenaline were obtained in the presence of ICI118551 
(50 nM) to selectively block β2ARs. To determine the effects of β2AR (Alexander et al., 
2011) -selective activation, concentration-effect curves for (-)-adrenaline were determined in 
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the presence of CGP20712A (300 nM) to selectively block β1ARs (Kaumann et al., 1999). To 
assess the influence of the PDE3-selective inhibitor cilostamide (300 nM-1 µM) and the 
PDE4-specific inhibitor rolipram (1-10  on the effects of the catecholamines, a single 
concentration-effect curve for a catecholamine was obtained in the absence or presence of a 
PDE inhibitor. Trabeculae were incubated with PDE inhibitors for 30-45 minutes prior to 
commencement of catecholamine concentration-effect curves. At the completion of 
concentration-effect curves to catecholamines on right ventricular trabeculae the effects of a 
maximal concentration of (-)-isoprenaline (200 was determined. Since up to 20 
contracting trabeculae were obtained from the same heart, it was often possible to compare 
the influence of the PDE inhibitors on responses mediated through both β1ARs and β2-ARs as 
shown in the representative experiment of Figure 3.     
 
Analysis and statistics 
Responses of right ventricular trabeculae to catecholamines were expressed as percentage of 
the response to a maximally effective isoprenaline concentration (200 μM), administered 
after a complete concentration-effect curve. The catecholamine concentrations producing a 
half maximum response, –LogEC50M (pEC50), were estimated from fitting a Hill function 
with variable slopes to concentration-effect curves from individual experiments. The data are 
expressed as mean ± S.E.M. of n = number of patients or trabeculae as indicated. 
Significance of differences between means were assessed with the use of either Student’s t 
test or ANOVA followed by Tukey-Kramer Multiple comparisons ad hoc test at P<0.05 
using Instat software (GraphPad Software Inc., San Diego, CA).  
Concentration–response curves on left ventricular trabeculae from Oslo patients were 
constructed by estimating centiles (EC10–EC100) for the receptor selective effects for each 
experiment and calculating the corresponding means and the horizontal positioning expressed 
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as −log EC50M. All results are expressed as mean ± SEM and statistical significance assessed 
with Oneway ANOVA with a-priori Bonferroni corrections made for multiple comparisons. 
P < 0.05 was regarded as statistically significant. 
 
Drugs 
(-)-Adrenaline (+)-bitartrate salt, (-)-noradrenaline bitartrate salt (hydrate), prazosin 
hydrochloride, atropine sulphate were purchased from Sigma-Aldrich (St. Louis, MO, USA 
or Castle Hill, Australia). Rolipram, cilostamide, CGP20712A  (2-hydroxy-5-[2-[[2-hydroxy-
3-[4-[1-methyl-4-(trifluorometyl)-1H-imidazol-2-yl]phenoxy]propyl]amino]ethoxy]-
benzamide) and ICI118551 (1-[2,3-dihydro-7-methyl-1H-inden-4-yl]oxy-3-[(1-
methylethyl)amino]-2-butanol) were from Tocris Bioscience (Bristol, UK) or Sigma (Castle 
Hill, Australia). Stock solutions were prepared in purified water and kept at −20°C to avoid 
oxidation.  Further dilutions of the drugs were made fresh daily and kept cool (0–4°C) and 
dark.  Repetitive experiments showed that drug solutions treated in these ways, are stable.  
 
 
Results 
 
Chronic metoprolol treatment increases the inotropic potencies of catecholamines  
Chronic treatment of patients with metoprolol sensitized right ventricular trabeculae to the 
inotropic effects of (-)-noradrenaline and (-)-adrenaline. The inotropic potencies of (-)-
noradrenaline and (-)-adrenaline were increased 4-fold and 5-fold respectively in metoprolol-
treated (P < 0.05) compared to non-β-blocker-treated patients (Figure 1A and B, table 1).  
The lusitropic effects of (-)-noradrenaline, mediated through β1AR, were not significantly 
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enhanced but the t50-abbreviating potency of (-)-adrenaline increased 7-fold (P<0.001) by 
treatment of patients with metoprolol (Supplement Figure 1S A-D, Supplement table S2). 
These results are consistent with the upregulation of the β1AR density and enhanced inotropic 
responses through these receptors in metoprolol-treated patients (Heilbrunn et al., 1989; 
Sigmund et al., 1996).  
 
Cilostamide fails to potentiate the inotropic effects of catecholamines in right 
ventricular trabeculae from non-β-blocker-treated patients    
Cilostamide (300 nM) did not significantly increase contractile force or hasten relaxation in 
the presence of ICI118551 or CGP20712A in trabeculae from non-β-blocker-treated patients.  
Cilostamide did not potentiate the positive inotropic effects of (-)-noradrenaline or (-)-
adrenaline (Figure 2, table 1). Cilostamide did not affect the lusitropic effects of (-)-
noradrenaline (Figure S2 A,C, table S2) but potentiated the (-)-adrenaline-evoked shortening 
of t50 (Figure S2 D, table S2)  
 
Cilostamide potentiates more the effects mediated through β2ARs than β1ARs in 
ventricular trabeculae from metoprolol-treated patients 
Cilostamide (300nM) did not significantly change contractile force in the presence of 
ICI118551 or CGP20712 on right ventricular trabeculae. Cilostamide caused left-ward shifts 
of the inotropic concentration-effect curves of (-)-noradrenaline and  (-)-adrenaline as shown 
in the representative experiment of Figure 3. Inotropic results from right ventricular 
trabeculae of 7 patients are shown in Figure 4. Cilostamide almost significantly increased the 
inotropic potency of (-)-noradrenaline (P=0.06) (Figure 4A, table 1). When data from right 
ventricular trabeculae of two additional metoprolol-treated Oslo patients (Results not shown) 
were pooled with the data from 7 Brisbane-Dresden patients, cilostamide significantly 
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(P<0.02, n=9) potentiated the inotropic effects of (-)-noradrenaline. Cilostamide (300 nM) 
potentiated the effects of (-)-adrenaline on force (5-fold, P < 0.05, Figure 4B, table 1). 
Cilostamide potentiated 3-fold the effects of (-)-noradrenaline on t50 (P < 0.05) but not TPF 
(Figure S3A,C, table S2). Cilostamide potentiated the effects of (-)-adrenaline on TPF (3-
fold) and t50 (4-fold) respectively (both P < 0.05, Supplement Figure S3B,D, table S2). 
 
Cilostamide (1 µM) caused a non-significant (P < 0.07) leftward shift of the concentration-
effects curve for the inotropic effects of (-)-noradrenaline on left ventricular trabeculae 
(P<0.07, Figure 5A, table 1), but potentiated the inotropic effects of (-)-adrenaline 5-fold 
(P<0.05, Figure 5B, table 1).  
 
Cilostamide did not potentiate the TPF effects of (-)-noradrenaline or (-)-adrenaline on left 
ventricular trabeculae but potentiated the effects on time to reach 80% relaxation 4-fold and 
5-fold respectively (both P < 0.05, Figure 4S, table S3).  
 
Cilostamide caused a non-significant trend of greater potentiation of the inotropic effects of  
(-)-adrenaline through β2AR (0.80±0.11 log units, n=9) than (-)-noradrenaline through β1AR 
in right ventricular trabeculae from metoprolol-treated patients (0.48±0.18 log units, n=9, 
Brisbane/Dresden/Oslo hearts (P=0.14, paired Student’s t-test). However, when all right and 
left ventricular inotropic data from metoprolol-treated patients were pooled, cilostamide (0.3-
1 μM) potentiated significantly more the β2AR-mediated effects of (-)-adrenaline (0.78±0.12 
log units, n=15) than the β1AR-mediated effects of (-)-noradrenaline (0.47±0.12 log units, 
n=15) (P=0.037). These results suggest that PDE3 limits more the inotropic responses 
through β2AR than β1AR. 
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Rolipram does not modify inotropic and lusitropic potencies of (-)-noradrenaline   and 
(-)-adrenaline    
Rolipram did not significantly modify force, TPF and t50 or t80 in right and left ventricular 
trabeculae incubated with ICI118551 or CGP20712A. The inotropic and lusitropic effects of 
(-)-noradrenaline and (-)-adrenaline were not significantly changed by rolipram (1 μM) in 
right ventricular trabeculae (inotropic, Figures 3 and 4, table 1;lusitropic Figure S3, table S2) 
and rolipram (10 μM) in left ventricular trabeculae (inotropic Figure 5, table 1; lusitropic 
Figure S4, table S3).  
 
The effects of the combination of cilostamide (300 nM) and rolipram (1 μM) on the inotropic  
and lusitropic potencies of (-)-noradrenaline and (-)-adrenaline were investigated in 3 
metoprolol-treated patients. Cilostamide + rolipram potentiated the inotropic ((-)-
noradrenaline P < 0.05; (-)-adrenaline P < 0.05) and lusitropic ((-)-noradrenaline TPF, t50 
both P < 0.05; (-)-adrenaline TPF, t50 both P < 0.05) effects of both (-)-noradrenaline and (-)-
adrenaline, but the degree of potentiation did not significantly (P > 0.05) differ from the 
potentiation caused by cilostamide alone (inotropic Figure 6; lusitropic Figure S5).  
 
Discussion 
Our work revealed two important aspects of the control by PDEs of the inotropic effects of 
catecholamines. Chronic treatment of heart failure patients with metoprolol induced PDE3 to 
reduce the inotropic responses more through β2ARs than β1ARs. PDE4 appears not to be 
involved in the inotropic and lusitropic control at all. 
 
Control by PDE3 of the function of β1ARs and β2ARs in heart failure patients treated with 
metoprolol.  
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PDE3 activity is stimulated by activation of β1ARs and β2ARs, which in turn causes a 
negative feedback by hydrolysing cAMP and thereby reducing inotropic and lusitropic 
effects. A tonic receptor activation by endogenous catecholamines increases cAMP and PKA 
activity in a compartment that allows the latter to phosphorylate and activate PDE3 (Gettys et 
al., 1987), which in turn hydrolyses cAMP. This effect is likely to be more important for 
β2AR, at least in human heart, because these receptors are more efficient than β1AR at 
activating Gs and stimulating ventricular adenylyl cyclase (Kaumann and Lemoine, 1987), as 
verified with recombinant receptors (Levy et al., 1993).  Therefore inhibition of PDE3 may 
potentiate β2AR-mediated responses more than β1AR-mediated responses, as shown here for 
human failing ventricle and previously for non-failing atrial myocardium from patients 
without heart failure (Christ et al., 2006a).   
 
A reduction in the expression and activity of PDE3 has been reported in heart failure patients 
(Silver et al., 1990; Ding et al., 2005a, 2005b). Treatment with isoprenaline causes sustained 
down-regulation of PDE3A Ding et al., 2005b), as also observed in human heart failure and 
animal heart failure models (Ya and Abe, 2007), presumably due to the high catecholamine 
plasma levels. A down-regulation of PDE3A would be expected to increase cAMP levels in 
heart failure so that inhibition of the enzyme would conceivably affect the effects of 
catecholamines less. The lack of significant potentiation by cilostamide of the inotropic and 
lusitropic effects of both (-)-noradrenaline through β1AR and marginal potentiation of the 
effects of adrenaline through β2AR in our 5 non-β-blocked patients is consistent with this 
expectation. In contrast, chronic treatment of heart failure patients with metoprolol revealed 
robust potentiation of the inotropic and lusitropic effects of the catecholamines through 
β1ARs and β2ARs. We speculate that this effect of metoprolol is due to chronic βAR 
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blockade, thereby preventing the suppressing effects of endogenous catecholamines on PDE3 
activity.   
 
The increased β2AR-mediated ventricular inotropic and lusitropic effects in ventricular 
trabeculae caused by metoprolol-treatment of heart failure patients agrees with a similar (6-
fold) enhancement of the β2AR-mediated inotropic potency of (-)-adrenaline in human atria 
obtained from patients without heart failure chronically treated with atenolol (Hall et 
al.,1990). The increased cardiac responsiveness to adrenaline through β2AR appears to be the 
result of chronic β1AR blockade. Experimental long-lasting exposure to catecholamines 
elicits upregulation of Giα (Eschenhagen et al., 1992). A similar situation occurs in heart 
failure in which the sympathetic nervous system is hyperactive (Cohn, 1989), plasma 
noradrenaline levels are increased (Thomas and Marks, 1978) and ventricular Giincreased 
(Neumann et al., 1988). Human β2ARs can couple to and activate Gi, in addition to Gs, 
when they are stimulated by a very high isoprenaline concentration in human atrium (Kilts et 
al., 2000). Through chronic β1AR blockade of patients by treatment with metoprolol or 
possibly atenolol, the noradrenaline-induced elevation of Giα ceases, Giα levels are reduced 
(Sigmund et al., 1996), conceivably thereby favouring coupling of β2AR to Gs to allow 
enhanced inotropic and lusitropic effects of adrenaline through β2AR. This hypothesis 
requires future research.   
 
Our results suggest that chronic β-adrenoceptor-blockade facilitates the control by PDE3s of 
catecholamine effects, particularly through 2ARs. However, the generality of this argument 
has to be restricted to heart failure or it runs afoul because in atrial myocardium obtained 
from patients without heart failure we observed that cilostamide potentiated the effects of 
adrenaline, mediated through 2AR, more than the effects of noradrenaline, mediated through 
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1AR, regardless of whether or not patients had been treated with 1AR-selective blockers 
(Christ et al., 2006a).  Changes of ventricular β2AR function in heart failure (Nikolaev et al., 
2010) and profound anatomical differences between ventricle and atrium (Bootman et al., 
2011) may be relevant to account for the different consequences of PDE3 control in the two 
tissues with respect to β1AR and β2AR function after chronic βAR blockade. 
 
The lusitropic (Figures S3-5, tables S2, S3) effects mediated through β1AR and β2AR were 
usually potentiated by cilostamide to a similar extent as the corresponding inotropic effects in 
trabeculae from β-blocked-treated patients (Figures 4-6, table 1). PDE3 activity in human 
ventricle is associated with membrane vesicle-derived t-tubules and junctional SR, causing 
hydrolysis of cAMP in the vicinity of phospholamban (Movsesian et al., 1991; Lugnier et al., 
1993). In ventricular myocardium from failing hearts noradrenaline and adrenaline produce 
similar increases in PKA-catalysed phosphorylation of the proteins mediating myocardial 
relaxation, phospholamban (PLB) (at Ser16), troponin-I (TnI) and cardiac myosin-binding 
protein-C (Kaumann et al., 1999). Our lusitropic results are consistent with an increased 
phosphorylation of PLB, TnI and myosin-binding protein-C by isoprenaline in the presence 
of the PDE3 inhibitor pimobendan in human failing myocardium (Bartel et al., 1996).  
 
PDE4 inhibition does not affect the inotropic and lusitropic effects of catecholamines 
PDE4 isoenzymes, their subtypes and splicing variants, are equally expressed in rodent and 
human ventricle but murine hearts have a considerably higher PDE4 activity than human 
hearts (Richter et al., 2011). Inhibition of PDE4 causes potentiation of the positive inotropic 
effects mediated through rodent β1ARs (Kaumann, 2011). In contrast, our results from human 
failing ventricle demonstrate that inhibition of PDE4 with rolipram did not potentiate the 
positive inotropic and lusitropic effects of (-)-noradrenaline and (-)-adrenaline, mediated 
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through β1AR and β2AR respectively. It could be argued that we were unable to demonstrate 
a potentiating effect of rolipram because PDEs, including PDE4s, are downregulated in heart 
failure (Ding et al., 2005a; 2005b; Lehnhardt et al., 2005). However, we have also reported 
for human atrial myocardium, obtained from non-failing hearts, that rolipram failed to 
potentiate the positive inotropic effects of (-)-noradrenaline  and (-)-adrenaline mediated 
through β1AR and β2AR (Christ et al., 2006a; Kaumann et al., 2007). Our findings are 
consistent with an early report demonstrating that cilostamide but not rolipram inhibited SR-
associated PDE activity in human ventricle from heart failure patients (Movsesian et al., 
1991).     
 
Taken together, our present results and a critical appraisal of the literature make it unlikely 
that PDE4s modulate human inotropic and lusitropic effects of catecholamines, mediated 
through both β1AR and β2AR in non-failing and failing hearts. Moreover, extrapolation of 
results from the PDE4 function in mouse and rat hearts to human inotropic and lusitropic 
effects of physiological catecholamines can actually be misleading. However, PDE4s can 
reduce the occurrence of catecholamine-evoked arrhythmias in murine ventricle (Galindo-
tovar and Kaumann, 2008; Lehnhardt et al., 2005) and apparently in human atrium (Molina et 
al., 2012). However, clinical trials with a PDE4 inhibitor, roflumilast, have not provided 
evidence for cardiovascular side effects in approximately 1,500 roflumilast-treated patients 
compared to 1,500 placebo patients (Calverley et al., 2009). A comparison between human 
and other species of the control of β1AR and β2AR-mediated inotropy and lusitropy by PDE3 
and PDE4, as well as protection against arrhythmias, is summarised in table S4.  
 
Clinical implications 
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Although we did not detect a direct inotropic change with cilostamide, this PDE3 inhibitor 
potentiated the inotropic effects of the endogenous catecholamines mediated through 
ventricular β1ARs and β2ARs of metoprolol-treated patients, consistent with PDE3 inhibition. 
The induction of PDE3 activity in metoprolol-treated patients could further reduce 
cardiostimulation by endogenous catecholamines. 
 
We found on human atrium that metoprolol blocks the effects catecholamines through β1ARs 
only by 2.5-fold more than β2ARs (Supplement Figure S6). We predict that heart failure 
patients under therapy with a PDE3 inhibitor + metoprolol could be at risk of not being 
protected against adverse stress-induced surges of adrenaline, acting through β2ARs. From 
simple competitive inhibition, the concentration-ratio (CR) of a catecholamine in the 
presence and absence of metoprolol can be calculated from CR = 1 + ([metoprolol] × KB-1). 
The therapeutic plasma level of 100 ng.ml-1 (310 nM) metoprolol (Kindermann et al., 2004) 
which hardly binds to plasma proteins, using KB values of 40 nM for β1AR and 98 nM for 
β2AR (Supplement Figure S6) would produce CR values of 8.8 for β1ARs and 4.2 for β2ARs. 
The 5-fold potentition of the inotropic effects of (-)-adrenaline by cilostamide suggests that 
endogenous increases in plasma (-)-adrenaline could conceivably surmount the β2AR 
blockade caused by metoprolol in patients also treated with a PDE3 inhibitor. 
 
Conclusions 
Treatment with metoprolol induces the control by PDE3 of the ventricular inotropic and 
lusitropic effects of (-)-noradrenaline and (-)-adrenaline through β1ARs and β2ARs 
respectively, plausibly by restoring the decreased activity and expression of PDE3 in heart 
failure. Quantitative considerations, based on differences in the affinity profile metoprolol for 
β1ARs and β2ARs, suggest that treatment with a PDE3-selective inhibitor could potentially 
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facilitate adverse stress-induced adrenaline effects through β2ARs in patients treated with 
metoprolol. PDE4 does not control the inotropic and lusitropic effects mediated through 
β1ARs and β2ARs in human heart. 
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Table  1 Inotropic potencies of (-)-noradrenaline and (-)-adrenaline, acting through ventricular β1- and β2-adrenoceptors respectively. Effects of 
cilostamide (300nM right ventricle, 1 µM left ventricle) and rolipram (1μM right ventricle, 10 μM left ventricle ) and chronic metoprolol treatment. 
.    (-)-Noradrenaline    (-)-Adrenaline____________________________ 
.   Non-B    Metoprolol treated  Non-βB    Metoprolol treated 
Right Ventricle 
.   pEC50  (n)   pEC50  (n)  pEC50  (n)  pEC50  (n)   
Control   5.65 ± 0.15 (11/4) 6.25 ± 0.13 (18/7)* 5.70 ± 0.27 (14/5) 6.40 ± 0.11 (18/7)* 
Cilostamide  5.89 ± 0.24 (10/4) 6.75 ± 0.17 (17/7) 6.19 ± 0.27 (12/5) 7.11 ± 0.16 (13/7)† 
Rolipram     6.19 ± 0.15 (15/7)    6.50 ± 0.17 (12/7) 
 
Left Ventricle 
Control      6.34 ± 0.16 (7/6)    6.26 ± 0.16 (10/7) 
Cilostamide     6.77 ± 0.19 (7/6)    6.93 ± 0.12 (8/7)†† 
Rolipram     6.25 ± 0.10 (7/6)    6.29 ± 0.17 (8/7) 
________________________________________________________________________________________________________________________________ 
Non-β: not treated with β-blockers  
*P < 0.05 vs non-B  
†P < 0.001 Paired Student’s t-test for comparison between Cilostamide and Control (no phosphodiesterase inhibitor) 
†† P < 0.05 vs. control, Oneway ANOVA with Bonferroni adjustment for multiple a-priori comparisons for comparison between cilosotamide, rolipram and Control. 
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Figure legends 
 
Figure 1 Effects of chronic administration of metoprolol compared to no--blocker on inotropic effects  of (-)-
noradrenaline through activation of β1-adrenoceptors (A) and (-)-adrenaline through activation of 2-
adrenoceptors (B) in right ventricular trabeculae from failing hearts. Note the increased potency of (-)-
noradrenaline and (-)-adrenaline for inotropic effects in metopolol treated patients. See text and table 1 for 
further detail. βAR-blockade did not significantly  increase basal force (P=0.07 for (-)-noradrenaline, P=0.095 
for (-)-adrenaline) and Emax  (P=0.10 for (-)-noradrenaline , P=0.054 for (-)-adrenaline). Data from 4 ((-)-
noradrenaline experiments) or 5 ((-)-adrenaline experiments) patients with heart failure not treated with a -
blocker and 7 patients with heart failure treated with metoprolol.  
 
Figure 2 Lack of effect of cilostamide on the inotropic responses of (-)-noradrenaline and (-)-adrenaline in 
right ventricular trabeculae from 4 ((-)-noradrenaline experiments) or 5 ((-)-adrenaline experiments) patients 
with heart failure not treated with a -blocker. Shown are concentration-effect curves to (-)-noradrenaline (A) 
and (-)-adrenaline (B) in the absence or presence of cilostamide (300 nM).  Cilostamide did not significantly 
increase basal force (P=0.36 for the noradrenaline group, P=0.46 for the adrenaline group) or enhance the 
maximum force caused by (-)-noradrenaline (P=0.41) or (-)-adrenaline (P=0.13). 
 
Figure 3 Representative experiment carried out on right ventricular trabeculae obtained from a 48 year old 
male patient with ischemic heart disease, left ventricular ejection fraction 25 %, chronically administered 
metoprolol 142.5 mg daily. Shown are original traces for (-)-noradrenaline and (-)-adrenaline in the absence or 
presence of cilostamide (Cil, 300 nM), rolipram (Rol, 1 µM) or Cil + Rol, followed by (-)-isoprenaline (ISO, 
200 µM). The bottom panels show the corresponding graphical representation with non-linear fits. Note the 
clear potentiation of inotropic effects of both (-)-noradrenaline and (-)-adrenaline in the presence of 
cilostamide but the lack of potentiation by rolipram.   
 
Figure 4 Potentiation of the inotropic effects of (-)-adrenaline by cilostamide (P < 0.05) in right ventricular 
trabeculae from seven patients from Brisbane/Dresden with heart failure chronically administered metoprolol 
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(B). In the same hearts cilostamide caused a leftward shift of the inotropic effects of (-)-noradrenaline (A) 
which was not quite significant (P = 0.06).  Rolipram had no effect on the inotropic effects of (-)-
noradrenaline or (-)-adrenaline. See text for further explanation.  Shown are concentration-effect curves to (-)-
noradrenaline (A) and (-)-adrenaline (B) in the absence or presence of cilostamide (300 nM) or rolipram (1 
µM).  
 
Figure 5  
Cilostamide potentiates the inotropic effects of (-)-adrenaline in left ventricular trabeculae from seven ((-)-
noradrenaline experiments), or eight Oslo patients ((-)-adrenaline experiments) with heart failure and 
chronically administered metoprolol. Shown are concentration-effect curves to (-)-noradrenaline (A) and (-)-
adrenaline (B) in the absence or presence of cilostamide (1 µM) or rolipram (10 µM). Inotropic data are 
normalized as a percentage of the maximal response to (-)-noradrenaline or (-)-adrenaline.    
 
Figure 6 Effects of the combination of cilostamide and rolipram on the inotropic responses of (-)-
noradrenaline (A) and (-)-adrenaline (B) in right ventricular trabeculae from 3 patients with heart failure and 
chronically administered metoprolol. Whilst the combination of cilostamide and rolipram potentiated the 
inotropic responses of (-)-noradrenaline and (-)-adrenaline, the degree of potentiation did not differ from that 
caused by cilostamide alone.  
 
